Evaluation of a modified hsCRP method for point-of-service testing [2]

Clinica Chimica Acta

Volumn 334, Issue 1-2, 2003, Pages 249-252

  Larsson, Anders ^a   Hansson, Lars Olof ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; C REACTIVE PROTEIN; GOLD; MONOCLONAL ANTIBODY; THYROTROPIN;

BLOOD SAMPLING; CONJUGATE; DEVICE; DIAGNOSTIC ACCURACY; EVALUATION; HUMAN; LETTER; LIFESTYLE; PRIORITY JOURNAL; PROTEIN MODIFICATION; RELIABILITY; TECHNIQUE;

EID: 12444309277     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00226-2     Document Type: Letter

References (14)

1. Libby P. Inflammation in atherosclerosis. Nature. 420:2002;868-874.
2. Morrow D.A., Rifai N., Antman E.M., Weiner D.L., McCabe C.H., Cannon C.P.et al. Serum amyloid a predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J. Am. Coll. Cardiol. 35:2000;358-362.
3. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 349:1997;462-466.
4. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336:1997;973-979.
5. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101:2000;1767-1772.
6. Wilkins J., Gallimore J.R., Moore E.G., Pepys M.B. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin. Chem. 44:1998;1358-1361.
7. Rifai N., Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 47:2001;403-411.
8. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 107:2003;363-369.
9. Yeh E.T., Willerson J.T. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 107:2003;370-371.
10. Tillet W.S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J. Exp. Med. 52:1930;561-571.
11. Ridker P.M. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 103:2001;1813-1818.
12. Chambers J.C., Eda S., Bassett P., Karim Y., Thompson S.G., Gallimore J.R.et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European Whites. Circulation. 104:2001;145-150.
13. Heilbronn L.K., Noakes M., Clifton P.M. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler. Thromb. Vasc. Biol. 21:2001;968-970.
14. Ridker P.M., Rifai N., Clearfield M., Downs J.S., Weis S., Miles J.S.et al. For the airforce/texas coronary atherosclerosis prevention study investigators. Measurement of c-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344:2001;1959-1965.